Incyte Reports 2023 Second Quarter Financial Results and Pro

WILMINGTON, Del.--(BUSINESS WIRE)--Aug 1, 2023--

Related Keywords

Canada , Austria , Germany , Norway , United States , Turkey , United Kingdom , France , Israel , Delaware , Japan , Switzerland , Russia , American , Ruxolitinib Jakavi , Baricitinib Olumiant , Retifanlimab Zynyz , Dashyant Dhanak , July Incyte , Greg Shertzer , Catalina Loveman , Pemigatinib Pemazyre , Tafasitamab Monjuvi , Ponatinib Iclusig , Capmatinib Tabrecta , Syndax Pharmaceuticals , Takeda Pharmaceuticals International , Millennium Pharmaceuticals Inc , Macrogenics Inc , Novartis , American Society Of Clinical Oncology , Xencor Inc , Drug Administration , Early Access Program , Pharmaceuticals Inc , Replimune Group Inc , Takeda Pharmaceutical Company , Incyte Corporation , Us Food Drug Administration , Cellenkos Inc , European Union , Exchange Commission , Chief Executive Officer , American Society , Clinical Oncology , Pivotal Phase , Replimune Group , Global Assessment Treatment Success , Three Phase , Two Phase , License Agreement , Chief Scientific Officer , Investigational New Drug , Quarter Financial , Accepted Accounting Principles , Royalty Revenues Product , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Medicinal Product , Millennium Pharmaceuticals , Condensed Consolidated Statements , Business Wire , Business , Ews Ap ,